|
|
Office Locations:
|
51 Astor Place, 10th Floor
New York, NY 10003
Phone: 646-205-5300
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $7.3 billion across their strategies. Perceptive Advisors has made global investments in public and private companies developing biotechnology products, drugs, medical devices and diagnostics. Perceptive established its Credit Opportunities strategy with the launch of its first closed-end fund in 2013. The firm currently manages approximately $1 Billion of capital dedicated to private credit, and provide customized debt financing solutions to innovative healthcare companies. Perceptive seeks to invest $10 - $100M for credit investments. Perceptive Advisors announced (May of 2021) the final closing of Perceptive Xontogeny Venture Fund II, LP (PXV Fund II) with $515 million in capital commitments in an oversubscribed fund to further the firm's early-stage life sciences platform.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
